<DOC>
	<DOCNO>NCT02910570</DOCNO>
	<brief_summary>This sub-study randomise , double blind , placebo-controlled , parallel group , single-centre trial investigate effect liraglutide body weight pain overweight obese patient knee osteoarthritis ( NCT02905864 ) . In parent trial patient subject run-in diet intervention phase ( week -8 0 ) include low-calorie diet dietetic counselling . At week 0 patient randomise receive either liraglutide 3 mg liraglutide 3 mg placebo add-on dietetic guidance re-introducing regular food focus continued motivation engage healthy lifestyle . This sub-study parent trial involve additional assessment skin auto fluorescence ( AGE concentration ) preallocation phase main trial phase , i.e . enrollment ( defined signature inform consent ) treatment allocation ( visit -Tx T0 parent trial visit schedule ) allocation end trial ( visit T0 T15 parent trial visit schedule ) .</brief_summary>
	<brief_title>Changes Skin Autoflouresence Following Weight Loss Maintenance Using Liraglutide Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Same parent trial ( NCT02905864 ) Informed consent obtain Clinical diagnosis knee OA ( American College Rheumatology ( ACR ) criterion ) confirm radiology restrict definite radiographic OA early moderatestages ( KellgrenLawrence grade 1 , 2 , 3 ) Age ≥ 18 year &lt; 75 year Body mass index ( BMI ) ≥ 27 kg/m2 Stable body weight previous 3 month ( &lt; 5 kg selfreported weight change ) Motivated weight loss Ongoing participation , participation within last 3 month , organise weight loss programme ( within last 3 month ) Current history treatment medication may cause significant weight gain least 3 month trial Current use use within three month trial GLP1 receptor agonist , pramlintide , sibutramine , orlistat , zonisamide , topiramate , phentermine Type 1 diabetes Type 2 diabetes treat glucoselowering drug metformin Alloplasty target knee joint ( see section 6.3 ) End stage disease target knee joint ( KellgrenLawrence grade 4 ) Immunoinflammatory disease Chronic widespread pain Pregnancy insufficient anticonception therapy female fertile patient Breastfeeding Estimated glomerular filtration rate ( eGFR ) &lt; 60 ml/min/1.73 m2 Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 x upper normal range ( UNR ) Surgery schedule trial duration period , except minor surgical procedure Surgical procedure arthroscopy injection knee within 3 month prior enrolment Previous surgical treatment obesity ( exclude liposuction &gt; 1 year trial entry ) Thyroid stimulate hormone ( TSH ) outside range 0.46.0 mIU/L Obesity secondary endocrinologic eat disorder treatment medicinal product may cause weight gain Family personal history medullary thyroid carcinoma multiple endocrine neoplasia type 2 Inflammatory bowel disease Congestive heart failure , New York Heart Association ( NYHA ) class IIIIV Diabetic gastroparesis History current diagnosis pancreatitis ( acute and/or chronic ) pancreatic cancer History cancer exception insitu malignancy skin cervix uteri History major depressive disorder , PHQ9 ( Patient Health Questionnaire9 ) score 15 , history severe psychiatric disorder diagnosis eat disorder Subjects lifetime history suicide attempt history suicidal behaviour within past month entry trial Inability speak Danish fluently A mental state impeding compliance program Use opioids similar strong analgesic Allergic reaction active ingredient Saxenda , hypotension , palpitation , dyspnoea oedema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>